Abstract
Long COVID is becoming a widespread issue, as some patients endure multi-system symptoms for months or even years post-acute infection, markedly diminishing their quality of life. A purely reactive approach to symptoms overlooks key opportunities for preventive intervention. From the standpoint of secondary prevention, this article re-examines how to spot people who might deteriorate, how to dynamically monitor their condition, and how to take action before permanent functional loss happens. The definition and phenotypic distinction of long-term COVID-19 are covered in the article, along with the potential role that risk models, biomarkers, and symptom scales can have in early detection. The article focuses on early interventions for the four main symptoms—fatigue, dyspnea, cognitive impairment, and autonomic dysfunction—such as multidisciplinary rehabilitation, cognitive behavioural therapy, and digital home-based rehabilitation. It also examines how proactive follow-up and digital monitoring can identify early signs of functional decline. However, the article does not ignore real-world challenges like accessibility and equity. Overall, lowering the burden of long-term COVID requires an individualised secondary preventive approach that is started shortly after acute infection and continued throughout. However, further implementation study is needed to determine whether this pathway is practical in health systems with various contexts and resources.
References
[1] World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1.
[2] Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934-1946. doi:10.1001/jama.2023.8823
[3] Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706-1714. doi: 10.1038/s41591-022-01909-w
[4] Sivan M, Wright S, Hughes S, et al. The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS): application and psychometric analysis in a post-COVID-19 syndrome cohort. J Med Virol. 2022;94(3):1027-1034. doi: 10.1002/jmv.27415
[5] Hughes SE, Haroon S, Subramanian A, et al. Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BMJ (Clinical research ed.), 377, e070230. doi:10.1136/bmj-2022-070230
[6] Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13:446. doi:10.1038/s41467-021-27797-1
[7] Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21:148. doi:10.1186/s12933-022-01579-5
[8] Greenhalgh T, Sivan M, Delaney B, Evans R, Milne R. Long covid—an update for primary care. BMJ. 2022;378:e072117. doi: 10.1136/bmj-2022-072117
[9] Radin JM, Vogel JM, Delgado F, et al. Long-term changes in wearable sensor data in people with and without Long Covid. NPJ Digit Med. 2024;7(1):246. http://dx.doi.org/10.1038/s41746-024-01238-x.
[10] Gloeckl R, Leitl D, Jarosch I, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res. 2021;7(2):00108-2021. DOI: 10.1183/23120541.00108-2021
[11] Kuut T A, Müller F, Csorba I, et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following coronavirus disease 2019: results of a randomized controlled trial. Clinical Infectious Diseases, 2023, 77(5): 687-695.http://dx.doi.org/10.1093/cid/ciad257
[12] León-Herrrera S, Oliván-Blázquez B, Sánchez-Recio R, et al. Effectiveness of an online multimodal rehabilitation program in long COVID patients: a randomized clinical trial. Arch Public Health. 2024;82:159. DOI: 10.1186/s13690-024-01354-w.
[13] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. DOI: 10.1038/s41579-022-00846-2

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Journal of Public Health and Preventive Medicine